Developer docs
API playgroundTry for free, no card

Search company profiles

Obsidian Therapeutics

Full company profile

uuid0000flo

Namestring
Obsidian Therapeutics
Legal namestring
Obsidian Therapeutics, Inc.
Websiteurl
obsidiantx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Obsidian Therapeutics is a clinical-stage biopharmaceutical company developing engineered tumor infiltrating lymphocyte (TIL) cell therapies for advanced solid tumors. Founded in 2015 and headquartered in Cambridge, Massachusetts with a manufacturing and process development facility in Bedford, Massachusetts, the company employs 101–250 people. Its lead product candidate, OBX-115 (also referenced as cytoTIL15), is an autologous TIL cell therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), designed to eliminate the need for toxic high-dose IL2 co-administration and to enable outpatient-compatible low-dose lymphodepletion. OBX-115 is currently in Phase 2 development for advanced melanoma refractory to immune checkpoint inhibitors and Phase 1 development for non-small cell lung cancer (NSCLC).

The company's core technology is the proprietary cytoDRiVE platform, which leverages drug responsive domains (DRDs) to enable precise, small-molecule-controlled regulation of therapeutic protein expression in engineered cell therapies. OBX-115 has received both FDA Fast Track Designation (July 2024) and Regenerative Medicine Advanced Therapy (RMAT) Designation (September 2024) for advanced melanoma, supporting a planned single-arm accelerated approval pathway. Phase 2 data presented at ASCO 2026 reported a 67% objective response rate at the recommended Phase 2 dose (n=10/15), with no dose-limiting toxicities, no ICANS, no ICU transfers, and no treatment-related mortality.

Obsidian is pre-revenue, with revenue model dependent on future commercial product sales following regulatory approval. Distribution today is conducted entirely through multicenter clinical trials at major U.S. cancer centers (Memorial Sloan Kettering, MD Anderson, Brown Cancer Center). The company has raised approximately $325 million across Series A ($49.5M in 2017), Series B ($115M in 2021), and Series C ($160.5M in 2024), and in April 2026 announced a definitive all-stock merger with Galera Therapeutics (NASDAQ: GRTX) accompanied by a $350 million concurrent private placement financing, intended to take the combined company public on Nasdaq under the ticker OBX in Q3 2026 and to fund operations into the second half of 2028. Strategic partnerships include Bristol Myers Squibb (CD40L cell therapy license exercised 2020), Vertex Pharmaceuticals (gene editing collaboration, 2021), and MD Anderson Cancer Center (cytoTIL co-development).

Short descriptiontext

Obsidian Therapeutics is a clinical-stage biopharmaceutical company developing engineered tumor infiltrating lymphocyte (TIL) cell therapies for advanced solid tumors, with lead candidate OBX-115 in Phase 2 for melanoma and Phase 1 for NSCLC using its proprietary cytoDRiVE platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered cell therapy, tumor infiltrating lymphocytes, cell and gene therapy, biopharmaceutical development, adoptive immunotherapy
Industry1 code
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Engineered Cell Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical-stage biopharmaceutical development
TypeOne Time License
Description

Pre-revenue clinical-stage company developing engineered TIL cell therapies. Revenue will be generated from product sales upon regulatory approval. The company is not currently generating revenue from product sales.

obsidiantx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Obsidian Therapeutics develops engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors using its proprietary cytoDRiVE® platform, which leverages drug responsive domains (DRDs) and FDA-approved small molecules to control therapeutic protein expression. Its lead clinical candidate, OBX-115 (cytoTIL15), is an autologous TIL therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15) that eliminates the need for toxic high-dose IL2 and is compatible with outpatient low-dose lymphodepletion. OBX-115 is currently in Phase 2 for advanced melanoma and Phase 1 for NSCLC.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 67% objective response rate at RP2D in advanced melanoma (n=15, Phase 2 data January 2026)
+4 more records
Product overview1 text field

Obsidian Therapeutics is developing a pipeline of engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors. The company's proprietary cytoDRiVE® platform enables drug-responsive control of protein function using FDA-approved small molecules. Lead product OBX-115 (cytoTIL15) is an IL2-sparing engineered TIL therapy with regulatable membrane-bound IL15, currently in Phase 2 clinical trials for advanced melanoma and Phase 1 for non-small cell lung cancer.

Product and service2 records
1OBX-115 (cytoTIL15)
CategoryEngineered Cell Therapy / TIL Therapy
Description

Genetically engineered autologous tumor infiltrating lymphocyte (TIL) cell therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15) for patients with advanced or metastatic melanoma refractory to PD-1/PD-L1 immune checkpoint inhibitors, with expansion into NSCLC. The therapy eliminates the need for toxic high-dose IL2 co-administration, enables outpatient-compatible low-dose lymphodepletion, and is compatible with minimally invasive core needle biopsy tumor procurement.

2cytoDRiVE® Platform
CategoryPlatform Technology / Cell Therapy Engine
Description

Proprietary drug-responsive protein control platform leveraging drug responsive domains (DRDs) and FDA-approved small molecules to enable precise regulation of the timing and level of therapeutic protein expression in cell therapies. Licensed to Bristol Myers Squibb for a CD40L-expressing cell therapy candidate and used in collaboration with Vertex Pharmaceuticals for drug-responsive gene editing therapies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Obsidian and Galera entered into a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Obsidian Therapeutics, Inc. and trade on Nasdaq under ticker symbol OBX. Concurrent private placement financing of $350 million from institutional investors. Transaction expected to close Q3 2026 subject to stockholder and regulatory approvals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-18
Description

Strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL) for solid tumors. MD Anderson conducted the first-in-human single-center Phase 1 clinical trial of OBX-115 (NCT05470283).

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-18
Description

Strategic collaboration to develop novel cell therapies with tunable immunomodulatory factors, opening potential for CAR-T and other cellular medicines in new settings. Note: Celgene was acquired by Bristol Myers Squibb in 2019.

4Bristol Myers Squibb
Strategic tierCoreTypeTechnology or Integration
Description

Strategic collaboration established January 2019 for development of novel cell therapies using tunable immunomodulatory factors. Bristol Myers Squibb exercised option in September 2020 to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE technology for controlled expression of CD40L. Obsidian eligible for potential future milestone and royalty payments.

obsidiantx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration established April 2021 to discover novel therapies that regulate gene editing using Obsidian's cytoDRiVE platform technology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Iovance is the leader in TIL therapy with FDA-approved lifileucel for advanced melanoma. Both companies develop autologous tumor-infiltrating lymphocyte therapies for solid tumors, making Iovance Obsidian's most direct competitor and benchmark for commercial scale-up.

TypeDirect peer
Description

Lyell is developing next-generation TIL therapies enhanced with genetic modifications to improve T-cell persistence and resistance to exhaustion, directly comparable to Obsidian's mbIL15-armored OBX-115 approach in solid tumor indications.

TypeDirect peer
Description

Adaptimmune develops engineered T-cell receptor (TCR-T) therapies for solid tumors including MAGE-A4 targeted therapies. It is comparable as a cell therapy company pursuing solid tumor indications with genetically modified autologous T-cells.

4Bristol Myers Squibb
TypeBroad incumbent
Description

BMS is both an Obsidian partner (licensed cytoDRiVE-based CD40L program) and a broader competitor in cell therapy with approved CAR-T products (Breyanzi, Abecma). It is a relevant comparable as an established cell therapy company and strategic counterparty.

TypeEmerging player
Description

Allogene is developing allogeneic 'off-the-shelf' CAR-T therapies for hematologic and solid tumor malignancies. It is comparable as a clinical-stage cell therapy company working on next-generation engineered T-cell platforms with a different manufacturing paradigm than Obsidian's autologous approach.

TypeEmerging player
Description

Cellectis is a clinical-stage gene editing and cell therapy company developing allogeneic CAR-T and TCR-based therapies. It is comparable to Obsidian as a cell therapy innovator working on engineered T-cell platforms with proprietary genome-editing capabilities.

TypeBroad incumbent
Description

Sana is developing ex vivo and in vivo cell therapies across multiple modalities including engineered T-cells, iPSC-derived cells, and fusogen-mediated delivery. Comparable as a cell therapy company with broad platform reach that overlaps with Obsidian's engineered T-cell focus.

TypeDirect peer
Description

Poseida develops non-viral, piggyBac-engineered autologous and allogeneic CAR-T therapies. Comparable as a clinical-stage engineered T-cell therapy company pursuing solid and hematologic malignancies with proprietary platform technology.

TypeEmerging player
Description

CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-edited cell therapies including ex vivo and in vivo approaches. Comparable as a next-generation cell therapy developer using proprietary platform technology to engineer therapeutic cells.

TypeEmerging player
Description

Century is developing iPSC-derived allogeneic cell therapies engineered with multiple modalities to enhance persistence and efficacy. Comparable as a clinical-stage engineered cell therapy company using innovative platform approaches to address oncology indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors37 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Obsidian Therapeutics

Engineered Cell Therapyobsidiantx.com

Obsidian Therapeutics is a clinical-stage biopharmaceutical company developing engineered tumor infiltrating lymphocyte (TIL) cell therapies for advanced solid tumors, with lead candidate OBX-115 in Phase 2 for melanoma and Phase 1 for NSCLC using its proprietary cytoDRiVE platform.

What Obsidian Therapeutics does

Obsidian Therapeutics is a clinical-stage biopharmaceutical company developing engineered tumor infiltrating lymphocyte (TIL) cell therapies for advanced solid tumors. Founded in 2015 and headquartered in Cambridge, Massachusetts with a manufacturing and process development facility in Bedford, Massachusetts, the company employs 101–250 people. Its lead product candidate, OBX-115 (also referenced as cytoTIL15), is an autologous TIL cell therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), designed to eliminate the need for toxic high-dose IL2 co-administration and to enable outpatient-compatible low-dose lymphodepletion. OBX-115 is currently in Phase 2 development for advanced melanoma refractory to immune checkpoint inhibitors and Phase 1 development for non-small cell lung cancer (NSCLC).

The company's core technology is the proprietary cytoDRiVE platform, which leverages drug responsive domains (DRDs) to enable precise, small-molecule-controlled regulation of therapeutic protein expression in engineered cell therapies. OBX-115 has received both FDA Fast Track Designation (July 2024) and Regenerative Medicine Advanced Therapy (RMAT) Designation (September 2024) for advanced melanoma, supporting a planned single-arm accelerated approval pathway. Phase 2 data presented at ASCO 2026 reported a 67% objective response rate at the recommended Phase 2 dose (n=10/15), with no dose-limiting toxicities, no ICANS, no ICU transfers, and no treatment-related mortality.

Obsidian is pre-revenue, with revenue model dependent on future commercial product sales following regulatory approval. Distribution today is conducted entirely through multicenter clinical trials at major U.S. cancer centers (Memorial Sloan Kettering, MD Anderson, Brown Cancer Center). The company has raised approximately $325 million across Series A ($49.5M in 2017), Series B ($115M in 2021), and Series C ($160.5M in 2024), and in April 2026 announced a definitive all-stock merger with Galera Therapeutics (NASDAQ: GRTX) accompanied by a $350 million concurrent private placement financing, intended to take the combined company public on Nasdaq under the ticker OBX in Q3 2026 and to fund operations into the second half of 2028. Strategic partnerships include Bristol Myers Squibb (CD40L cell therapy license exercised 2020), Vertex Pharmaceuticals (gene editing collaboration, 2021), and MD Anderson Cancer Center (cytoTIL co-development).

Obsidian Therapeutics firmographics

Firmographics
Name
Obsidian Therapeutics
Legal name
Obsidian Therapeutics, Inc.
Website
https://obsidiantx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Obsidian Therapeutics is a clinical-stage biopharmaceutical company developing engineered tumor infiltrating lymphocyte (TIL) cell therapies for advanced solid tumors, with lead candidate OBX-115 in Phase 2 for melanoma and Phase 1 for NSCLC using its proprietary cytoDRiVE platform.
Ownership category
akta.pro rank

Obsidian Therapeutics industry classification

Industry
Product category
Engineered Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Engineered cell therapy
  • Tumor infiltrating lymphocytes
  • Cell and gene therapy
  • Biopharmaceutical development
  • Adoptive immunotherapy

Where Obsidian Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Obsidian Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Clinical-stage biopharmaceutical development: Pre-revenue clinical-stage company developing engineered TIL cell therapies. Revenue will be generated from product sales upon regulatory approval. The company is not currently generating revenue from product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Obsidian Therapeutics product offering

Product offering

Core offering

Obsidian Therapeutics develops engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors using its proprietary cytoDRiVE® platform, which leverages drug responsive domains (DRDs) and FDA-approved small molecules to control therapeutic protein expression. Its lead clinical candidate, OBX-115 (cytoTIL15), is an autologous TIL therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15) that eliminates the need for toxic high-dose IL2 and is compatible with outpatient low-dose lymphodepletion. OBX-115 is currently in Phase 2 for advanced melanoma and Phase 1 for NSCLC.

Product overview

Obsidian Therapeutics is developing a pipeline of engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors. The company's proprietary cytoDRiVE® platform enables drug-responsive control of protein function using FDA-approved small molecules. Lead product OBX-115 (cytoTIL15) is an IL2-sparing engineered TIL therapy with regulatable membrane-bound IL15, currently in Phase 2 clinical trials for advanced melanoma and Phase 1 for non-small cell lung cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • OBX-115 (cytoTIL15) Genetically engineered autologous tumor infiltrating lymphocyte (TIL) cell therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15) for patients with advanced or metastatic melanoma refractory to PD-1/PD-L1 immune checkpoint inhibitors, with expansion into NSCLC. The therapy eliminates the need for toxic high-dose IL2 co-administration, enables outpatient-compatible low-dose lymphodepletion, and is compatible with minimally invasive core needle biopsy tumor procurement.
  • cytoDRiVE® Platform Proprietary drug-responsive protein control platform leveraging drug responsive domains (DRDs) and FDA-approved small molecules to enable precise regulation of the timing and level of therapeutic protein expression in cell therapies. Licensed to Bristol Myers Squibb for a CD40L-expressing cell therapy candidate and used in collaboration with Vertex Pharmaceuticals for drug-responsive gene editing therapies.

Quantifiable outcome

  • 67% objective response rate at RP2D in advanced melanoma (n=15, Phase 2 data January 2026)
  • +4 more outcomes

Companies that use Obsidian Therapeutics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Obsidian Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Obsidian Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

  • Galera TherapeuticsflagshipStrategic or Co-development Partner · 14 April 2026Obsidian and Galera entered into a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Obsidian Therapeutics, Inc. and trade on Nasdaq under ticker symbol OBX. Concurrent private placement financing of $350 million from institutional investors. Transaction expected to close Q3 2026 subject to stockholder and regulatory approvals.
  • MD Anderson Cancer CentercoreStrategic or Co-development Partner · 18 November 2020Strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL) for solid tumors. MD Anderson conducted the first-in-human single-center Phase 1 clinical trial of OBX-115 (NCT05470283).
  • CelgeneminorStrategic or Co-development Partner · 18 January 2019Strategic collaboration to develop novel cell therapies with tunable immunomodulatory factors, opening potential for CAR-T and other cellular medicines in new settings. Note: Celgene was acquired by Bristol Myers Squibb in 2019.
  • Bristol Myers SquibbcoreTechnology or IntegrationStrategic collaboration established January 2019 for development of novel cell therapies using tunable immunomodulatory factors. Bristol Myers Squibb exercised option in September 2020 to an exclusive worldwide license to a cell therapy candidate based on Obsidian's cytoDRiVE technology for controlled expression of CD40L. Obsidian eligible for potential future milestone and royalty payments.
  • Vertex PharmaceuticalscoreStrategic or Co-development PartnerCollaboration established April 2021 to discover novel therapies that regulate gene editing using Obsidian's cytoDRiVE platform technology.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Obsidian Therapeutics competitors and assessment

Company assessment

Direct peers

  • Iovance Biotherapeutics: Iovance is the leader in TIL therapy with FDA-approved lifileucel for advanced melanoma. Both companies develop autologous tumor-infiltrating lymphocyte therapies for solid tumors, making Iovance Obsidian's most direct competitor and benchmark for commercial scale-up.
  • Lyell Immunopharma: Lyell is developing next-generation TIL therapies enhanced with genetic modifications to improve T-cell persistence and resistance to exhaustion, directly comparable to Obsidian's mbIL15-armored OBX-115 approach in solid tumor indications.
  • Adaptimmune: Adaptimmune develops engineered T-cell receptor (TCR-T) therapies for solid tumors including MAGE-A4 targeted therapies. It is comparable as a cell therapy company pursuing solid tumor indications with genetically modified autologous T-cells.
  • Poseida Therapeutics: Poseida develops non-viral, piggyBac-engineered autologous and allogeneic CAR-T therapies. Comparable as a clinical-stage engineered T-cell therapy company pursuing solid and hematologic malignancies with proprietary platform technology.

Broad incumbents

  • Bristol Myers Squibb: BMS is both an Obsidian partner (licensed cytoDRiVE-based CD40L program) and a broader competitor in cell therapy with approved CAR-T products (Breyanzi, Abecma). It is a relevant comparable as an established cell therapy company and strategic counterparty.
  • Sana Biotechnology: Sana is developing ex vivo and in vivo cell therapies across multiple modalities including engineered T-cells, iPSC-derived cells, and fusogen-mediated delivery. Comparable as a cell therapy company with broad platform reach that overlaps with Obsidian's engineered T-cell focus.

Emerging players

  • Allogene Therapeutics: Allogene is developing allogeneic 'off-the-shelf' CAR-T therapies for hematologic and solid tumor malignancies. It is comparable as a clinical-stage cell therapy company working on next-generation engineered T-cell platforms with a different manufacturing paradigm than Obsidian's autologous approach.
  • Cellectis: Cellectis is a clinical-stage gene editing and cell therapy company developing allogeneic CAR-T and TCR-based therapies. It is comparable to Obsidian as a cell therapy innovator working on engineered T-cell platforms with proprietary genome-editing capabilities.
  • CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing company developing CRISPR/Cas9-edited cell therapies including ex vivo and in vivo approaches. Comparable as a next-generation cell therapy developer using proprietary platform technology to engineer therapeutic cells.
  • Century Therapeutics: Century is developing iPSC-derived allogeneic cell therapies engineered with multiple modalities to enhance persistence and efficacy. Comparable as a clinical-stage engineered cell therapy company using innovative platform approaches to address oncology indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Obsidian Therapeutics social profiles

Digital presence

Obsidian Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Obsidian Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Obsidian Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors37 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Obsidian Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Obsidian Therapeutics

What does Obsidian Therapeutics do?

Obsidian Therapeutics develops engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors using its proprietary cytoDRiVE® platform, which leverages drug responsive domains (DRDs) and FDA-approved small molecules to control therapeutic protein expression. Its lead clinical candidate, OBX-115 (cytoTIL15), is an autologous TIL therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15) that eliminates the need for toxic high-dose IL2 and is compatible with outpatient low-dose lymphodepletion. OBX-115 is currently in Phase 2 for advanced melanoma and Phase 1 for NSCLC.

Is Obsidian Therapeutics a public or private company?

Obsidian Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Obsidian Therapeutics founded?

Obsidian Therapeutics was founded in 2017. It employs 101 to 250 people.

Where is Obsidian Therapeutics based?

Obsidian Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Obsidian Therapeutics make money?

One revenue line is on record: clinical-stage biopharmaceutical development.

Who are Obsidian Therapeutics's main competitors?

Direct peers on record are Iovance Biotherapeutics, Lyell Immunopharma, Adaptimmune and Poseida Therapeutics. Broad incumbents are Bristol Myers Squibb and Sana Biotechnology. Emerging players are Allogene Therapeutics, Cellectis, CRISPR Therapeutics and Century Therapeutics.

Does Obsidian Therapeutics have an API?

No public API is recorded for Obsidian Therapeutics.

What industry is Obsidian Therapeutics in?

Obsidian Therapeutics's product category is Engineered Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaObsidian Therapeutics, Inc. reports Q3 resultsObsidian Therapeutics reported Q3 GAAP EPS of -$1.23, with net loss widening 78% year-over-year to $50.7M. Cash, cash equivalents, and marketable securities totaled $324.4M as of September 30, 2026, and the company expects cash runway into the second half of 2028.Business Wire BlogObsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesObsidian Therapeutics reported Q3 2026 results, including a $350 million oversubscribed financing and a Nasdaq debut. The company presented updated amsoki-cel data showing a 67% ORR and 8.3-month median PFS in advanced melanoma. It expects topline data by year-end 2027.TradingViewObsidian Therapeutics (OBX) Reports 33% of Patients in Response at Month 12Obsidian Therapeutics reported updated amsoki-cel data in ICI-resistant advanced melanoma, with 33% of patients at the recommended dose remaining in response at month 12. Median progression-free survival was 8.3 months, and median response duration was not reached at 14.3-month median follow-up. The registration-enabling cohort is expected to complete by Q1 2027.American Banking and Market NewsObsidian Therapeutics (OBX) – What Are Brokerages Thinking About This Stock?Obsidian Therapeutics has an average broker rating of Moderate Buy, with seven firms covering the stock. Analysts set a twelve-month price target of $39.00, and the stock opened at $14.59 with a fifty-two-week range of $11.52 to $49.97.Markets DailyObsidian Therapeutics (NASDAQ:OBX) Upgraded at Wall Street ZenWall Street Zen upgraded Obsidian Therapeutics from a sell to a hold rating. The stock has an average rating of Moderate Buy with a consensus target price of $39.00. Obsidian Therapeutics is a clinical-stage biopharmaceutical company developing engineered TIL cell therapies for solid tumors.MarketBeatObsidian Therapeutics (NASDAQ:OBX) Upgraded to Hold at Wall Street ZenWall Street Zen upgraded Obsidian Therapeutics from a sell to a hold rating. The stock opened at $13.98, with a consensus rating of Moderate Buy and a price target of $39.00. The company develops engineered TIL cell therapies for solid tumors.American Banking and Market NewsObsidian Therapeutics (NASDAQ:OBX) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Obsidian Therapeutics from a hold to a sell rating. The stock opened at $11.77, with a consensus rating of Moderate Buy and an average target price of $39.00. The company develops engineered cell and gene therapies.MarketBeatObsidian Therapeutics (NASDAQ:OBX) Shares Shorted: Short Interest Up 249.5% in SeptemberObsidian Therapeutics saw short interest rise 249.5% to 884,528 shares as of September 30th, with 1.4% of shares sold short. Analysts rate the stock a Moderate Buy with an average target price of $39.00.American Banking and Market NewsObsidian Therapeutics (NASDAQ:OBX) Stock Has Average Price Target of $39.00Obsidian Therapeutics shares received an average "Moderate Buy" rating from seven brokerages, with an average 1-year price target of $39.00. The stock opened at $13.59, with a 50-day moving average of $18.85 and a 52-week range of $12.16 to $49.97. The company develops engineered cell and gene therapies, including its CytoDRiVE platform.Investing.comObsidian to present melanoma therapy data at November conferenceObsidian Therapeutics will present updated clinical data for its amsoki-cel T cell therapy at the Society for Immunotherapy of Cancer Annual Meeting in Phoenix from November 4-8, 2026. The company will share pooled safety and efficacy results from two Phase 1 studies in patients with immune-checkpoint inhibitor-resistant advanced melanoma.